Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
Conditions:   Hematopoietic and Lymphoid Cell Neoplasm;   Malignant Solid Neoplasm;   Steroid-Refractory Pneumonitis
Interventions:   Biological: Infliximab;   Biological: Intravenous Immunoglobulin Therapy;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2020 / by / in
Comments